Also, a study suggested treatment of CPL is responsible for activation of ERK1/2 causing apoptosis in renal cells through TP53 and Bax pathway (Liu et al. 2019; Zhuang and Schnellmann 2006). The gene discussed is TP53; the disease is congenital pulmonary lymphangiectasia.